Zyphar'S Biopharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 21-06-2024
- Paid Up Capital ₹ 2.00 Cr
as on 21-06-2024
- Company Age 3 Year, 15 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.70 Cr
as on 21-06-2024
- Revenue %
(FY 2023)
- Profit 363.10%
(FY 2023)
- Ebitda -5495.71%
(FY 2023)
- Net Worth 5415.94%
(FY 2023)
- Total Assets 1004.87%
(FY 2023)
About Zyphar'S Biopharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 2.00 Cr.
The company currently has active open charges totaling ₹5.70 Cr.
Rajeshkumar Jain and Dinesh Sakhariya serve as directors at the Company.
- CIN/LLPIN
U24299PN2021PTC206752
- Company No.
206752
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Dec 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Zyphar'S Biopharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajeshkumar Jain  | Director | 08-Dec-2021 | Current |
| Dinesh Sakhariya | Director | 08-Dec-2021 | Current |
Financial Performance of Zyphar'S Biopharmaceuticals.
Zyphar'S Biopharmaceuticals Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 363.1% increase in profit. The company's net worth Soared by an impressive increase of 5415.94%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Zyphar'S Biopharmaceuticals?
In 2023, Zyphar'S Biopharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Jodhawat Construction Company Private LimitedActive 16 years 5 months
Rajeshkumar Jain is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 27 Apr 2023 | ₹5.70 Cr | Open |
How Many Employees Work at Zyphar'S Biopharmaceuticals?
Zyphar'S Biopharmaceuticals has a workforce of 19 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Zyphar'S Biopharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zyphar'S Biopharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
